AP NEWS

The Global Chemotherapy-Induced Nausea & Vomiting (CINV) Treatment Market 2018-2026: Analysis by Drug Class and Geography - ResearchAndMarkets.com

September 18, 2018

DUBLIN--(BUSINESS WIRE)--Sep 18, 2018--The “Global Chemotherapy Induced Nausea and Vomiting Treatment Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2018 To 2026” report has been added to ResearchAndMarkets.com’s offering.

The global chemotherapy induced nausea and vomiting market was valued at US$ 2,057.4 Mn in 2017, and is expected to reach US$ 3,626.1 Mn by 2026, expanding at a CAGR of 6.5% from 2018 to 2026.

As per the latest research citings of National Cancer Institute, in 2016 there were approximately 15.5 million cancer survivors due to early intervention of chemotherapy. Business analysts predict the rise in survivors to be 20.3 million by 2030.Serotonin receptor antagonist represents a major share in the chemotherapy induced nausea and vomiting treatment market. Excellent pharmacodynamics properties of newer 5HT3 receptor antagonist and availability in oral, intravenous and transdermal patches makes it popular among the physicians treating CINV.Dopamine antagonist have found prominence in treating acute nausea with minimal side effects. NK1 receptor antagonist will project healthy growth during the forecast period on account of its optimum pharmacokinetic properties, and is found effective in the treatment of refractory nausea in patients suffering with chemotherapy induced nausea and vomiting.North America is the global leader in chemotherapy induced nausea and vomiting treatment market. Domicile of market leaders such as Sanofi-Aventis, Helsinn Healthcare etc., manufacturing CINV drugs and increasing demand for chemotherapy drive the CINV treatment market in North America.

Key Market Movements

Rising demand for chemotherapy as treatment option in patients suffering with cancerExcellent clinical outcomes of drug combination serotonin receptor antagonist/NK1 receptor antagonist in CINV treatmentAffordable reimbursement scenario for generic antiemetic drugs employed for CINV treatment

Key Topics Covered

Chapter 1. Preface

Chapter 2. Executive Summary

Chapter 3. Chemotherapy Induced Nausea and Vomiting Treatment Market: Dynamics and Future Outlook

Chapter 4. Global Chemotherapy Induced Nausea and Vomiting Treatment Market, by Drug Class

Chapter 5. Global Chemotherapy Induced Nausea and Vomiting Treatment Market, by Geography

Chapter 6. Company Profiles

Baxter PharmaceuticalsEisai, Inc.Helsinn HealthcareGlaxoSmithkline, PlcMerck & Co. Inc.ProStrakan, Inc.Pfizer, Inc.Sanofi-AventisSolvay Pharmaceuticals, Inc.Teva Pharmaceutical Industries Ltd.

For more information about this report visit https://www.researchandmarkets.com/research/w2g3b8/the_global?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20180918005430/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Gastrointestinal Drugs

KEYWORD:

INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 09/18/2018 05:28 AM/DISC: 09/18/2018 05:28 AM

http://www.businesswire.com/news/home/20180918005430/en

AP RADIO
Update hourly